Works by Cheng-Yuan Peng


Results: 107
    1
    2
    3

    Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.

    Published in:
    Liver International, 2018, v. 38, n. 5, p. 821, doi. 10.1111/liv.13596
    By:
    • Reddy, K. Rajender;
    • Pol, Stanislas;
    • Thuluvath, Paul J.;
    • Kumada, Hiromitsu;
    • Toyota, Joji;
    • Chayama, Kazuaki;
    • Levin, James;
    • Lawitz, Eric J.;
    • Gadano, Adrian;
    • Ghesquiere, Wayne;
    • Gerken, Guido;
    • Brunetto, Maurizia R.;
    • Peng, Cheng‐yuan;
    • Silva, Marcelo;
    • Strasser, Simone I.;
    • Heo, Jeong;
    • Mcphee, Fiona;
    • Liu, Zhaohui;
    • Yang, Rong;
    • Linaberry, Misti
    Publication type:
    Article
    4
    5

    Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.

    Published in:
    Liver International, 2016, v. 36, n. 12, p. 1755, doi. 10.1111/liv.13253
    By:
    • Su, Tung ‐ Hung;
    • Hu, Tsung ‐ Hui;
    • Chen, Chi ‐ Yi;
    • Huang, Yi ‐ Hsiang;
    • Chuang, Wan ‐ Long;
    • Lin, Chun ‐ Che;
    • Wang, Chia ‐ Chi;
    • Su, Wei ‐ Wen;
    • Chen, Ming ‐ Yao;
    • Peng, Cheng ‐ Yuan;
    • Chien, Rong ‐ Nan;
    • Huang, Yi ‐ Wen;
    • Wang, Horng ‐ Yuan;
    • Lin, Chih ‐ Lin;
    • Yang, Sheng ‐ Shun;
    • Chen, Tsung ‐ Ming;
    • Mo, Lein ‐ Ray;
    • Hsu, Shih ‐ Jer;
    • Tseng, Kuo ‐ Chih;
    • Hsieh, Tsai ‐ Yuan
    Publication type:
    Article
    6
    7

    A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.

    Published in:
    Liver International, 2016, v. 36, n. 8, p. 1101, doi. 10.1111/liv.13082
    By:
    • Kao, Jia ‐ Horng;
    • Chien, Rong ‐ Nan;
    • Chang, Ting ‐ Tsung;
    • Peng, Cheng ‐ Yuan;
    • Hu, Tsung ‐ Hui;
    • Lo, Gin ‐ Ho;
    • Wang, Horng ‐ Yuan;
    • Chen, Jyh ‐ Jou;
    • Yang, Jenny C.;
    • Knox, Steven J.;
    • Han, Lingling;
    • Mo, Hongmei;
    • Mathias, Anita;
    • Brainard, Diana M.;
    • Sheen, I ‐ Shyan;
    • Hsu, Yu ‐ Chun;
    • Chu, Chi ‐ Jen;
    • Chuang, Wan ‐ Long
    Publication type:
    Article
    8

    Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.

    Published in:
    Liver International, 2016, v. 36, n. 7, p. 954, doi. 10.1111/liv.13049
    By:
    • Kao, Jia ‐ Horng;
    • Jensen, Donald M.;
    • Manns, Michael P.;
    • Jacobson, Ira;
    • Kumada, Hiromitsu;
    • Toyota, Joji;
    • Heo, Jeong;
    • Yoffe, Boris;
    • Sievert, William;
    • Bessone, Fernando;
    • Peng, Cheng ‐ Yuan;
    • Roberts, Stuart K.;
    • Lee, Youn ‐ Jae;
    • Bhore, Rafia;
    • Mendez, Patricia;
    • Hughes, Eric;
    • Noviello, Stephanie
    Publication type:
    Article
    9
    10

    Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 2, p. 207, doi. 10.1159/000504650
    By:
    • Tseng, Tai-Chung;
    • Peng, Cheng-Yuan;
    • Hsu, Yao-Chun;
    • Su, Tung-Hung;
    • Wang, Chia-Chi;
    • Liu, Chun-Jen;
    • Yang, Hung-Chih;
    • Yang, Wan-Ting;
    • Lin, Chia-Hsin;
    • Yu, Ming-Lung;
    • Lai, Hsueh-Chou;
    • Tanaka, Yasuhito;
    • Nguyen, Mindie H.;
    • Liu, Chen-Hua;
    • Chen, Pei-Jer;
    • Chen, Ding-Shinn;
    • Kao, Jia-Horng
    Publication type:
    Article
    11

    Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2025, v. 61, n. 9, p. 1508, doi. 10.1111/apt.70029
    By:
    • Chang, Yu‐Ping;
    • Lee, Ji‐Yuh;
    • Chen, Chi‐Yi;
    • Kao, Wei‐Yu;
    • Lin, Chih‐Lin;
    • Yang, Sheng‐Shun;
    • Shih, Yu‐Lueng;
    • Peng, Cheng‐Yuan;
    • Lee, Fu‐Jen;
    • Tsai, Ming‐Chang;
    • Huang, Shang‐Chin;
    • Su, Tung‐Hung;
    • Tseng, Tai‐Chung;
    • Liu, Chun‐Jen;
    • Chen, Pei‐Jer;
    • Kao, Jia‐Horng;
    • Liu, Chen‐Hua
    Publication type:
    Article
    12

    Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.

    Published in:
    Viruses (1999-4915), 2022, v. 14, n. 2, p. 333, doi. 10.3390/v14020333
    By:
    • Chen, Yen-Chun;
    • Chang, Te-Sheng;
    • Chen, Chien-Hung;
    • Cheng, Pin-Nan;
    • Lo, Ching-Chu;
    • Mo, Lein-Ray;
    • Chen, Chun-Ting;
    • Huang, Chung-Feng;
    • Kuo, Hsing-Tao;
    • Huang, Yi-Hsiang;
    • Tai, Chi-Ming;
    • Peng, Cheng-Yuan;
    • Bair, Ming-Jong;
    • Yeh, Ming-Lun;
    • Lin, Chih-Lang;
    • Lin, Chun-Yen;
    • Lee, Pei-Lun;
    • Chong, Lee-Won;
    • Hung, Chao-Hung;
    • Huang, Jee-Fu
    Publication type:
    Article
    13
    14

    Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.

    Published in:
    Annals of Internal Medicine, 2022, v. 175, n. 9, p. 1221, doi. 10.7326/M21-4119
    By:
    • Grebely, Jason;
    • Dore, Gregory J.;
    • Altice, Frederick L.;
    • Conway, Brian;
    • Litwin, Alain H.;
    • Norton, Brianna L.;
    • Dalgard, Olav;
    • Gane, Edward J.;
    • Shibolet, Oren;
    • Nahass, Ronald;
    • Luetkemeyer, Anne F.;
    • Peng, Cheng-Yuan;
    • Iser, David;
    • Gendrano, Isaias Noel;
    • Kelly, Michelle M.;
    • Hwang, Peggy;
    • Asante-Appiah, Ernest;
    • Haber, Barbara A.;
    • Barr, Eliav;
    • Robertson, Michael N.
    Publication type:
    Article
    15
    16

    Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

    Published in:
    Clinical & Molecular Hepatology, 2024, v. 30, n. 3, p. 468, doi. 10.3350/cmh.2024.0038
    By:
    • Tsai, Pei-Chien;
    • Huang, Chung-Feng;
    • Yeh, Ming-Lun;
    • Hsieh, Meng-Hsuan;
    • Kuo, Hsing-Tao;
    • Hung, Chao-Hung;
    • Tseng, Kuo-Chih;
    • Lai, Hsueh-Chou;
    • Peng, Cheng-Yuan;
    • Wang, Jing-Houng;
    • Chen, Jyh-Jou;
    • Lee, Pei-Lun;
    • Chien, Rong-Nan;
    • Yang, Chi-Chieh;
    • Lo, Gin-Ho;
    • Kao, Jia-Horng;
    • Liu, Chun-Jen;
    • Liu, Chen-Hua;
    • Yan, Sheng-Lei;
    • Lin, Chun-Yen
    Publication type:
    Article
    17
    18

    Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.

    Published in:
    Clinical & Molecular Hepatology, 2024, v. 30, n. 1, p. 16, doi. 10.3350/cmh.2023.0315
    By:
    • Pin-Nan Cheng;
    • Wen-Jone Chen;
    • Charles Jia-Yin Hou;
    • Chih-Lin Lin;
    • Ming-Ling Chang;
    • Chia-Chi Wang;
    • Wei-Ting Chang;
    • Chao-Yung Wang;
    • Chun-Yen Lin;
    • Chung-Lieh Hung;
    • Cheng-Yuan Peng;
    • Ming-Lung Yu;
    • Ting-Hsing Chao;
    • Jee-Fu Huang;
    • Yi-Hsiang Huang;
    • Chi-Yi Chen;
    • Chern-En Chiang;
    • Han-Chieh Lin;
    • Yi-Heng Li;
    • Tsung-Hsien Lin
    Publication type:
    Article
    19

    Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.

    Published in:
    Clinical & Molecular Hepatology, 2021, v. 27, n. 4, p. 575, doi. 10.3350/cmh.2021.0155
    By:
    • Chen-Hua Liu;
    • Chi-Yi Chen;
    • Wei-Wen Su;
    • Chun-Jen Liu;
    • Ching-Chu Lo;
    • Ke-Jhang Huang;
    • Jyh-Jou Chen;
    • Kuo-Chih Tseng;
    • Chi-Yang Chang;
    • Cheng-Yuan Peng;
    • Yu-Lueng Shih;
    • Chia-Sheng Huang;
    • Wei-Yu Kao;
    • Sheng-Shun Yang;
    • Ming-Chang Tsai;
    • Jo-Hsuan Wu;
    • Po-Yueh Chen;
    • Pei-Yuan Su;
    • Jow-Jyh Hwang;
    • Yu-Jen Fang
    Publication type:
    Article
    20
    21

    Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 2, p. 217, doi. 10.1111/apt.17764
    By:
    • Fung, Scott K.;
    • Pan, Calvin Q.;
    • Wong, Grace Lai‐Hung;
    • Seto, Wai‐Kay;
    • Ahn, Sang Hoon;
    • Chen, Chi‐Yi;
    • Hann, Hie‐Won L.;
    • Jablkowski, Maciej S.;
    • Kim, Yoon Jun;
    • Yurdaydin, Cihan;
    • Peng, Cheng‐Yuan;
    • Nguyen, Tuan;
    • Yatsuhashi, Hiroshi;
    • Flaherty, John F.;
    • Yee, Leland J.;
    • Abramov, Frida;
    • Wang, Hongyuan;
    • Abdurakhmanov, Dzhamal;
    • Lim, Young‐Suk;
    • Buti, Maria
    Publication type:
    Article
    22
    23
    24

    Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 434, doi. 10.1111/apt.16697
    By:
    • Liu, Chen‐Hua;
    • Peng, Cheng‐Yuan;
    • Kao, Wei‐Yu;
    • Yang, Sheng‐Shun;
    • Shih, Yu‐Lueng;
    • Lin, Chin‐Lin;
    • Tsai, Meng‐Kun;
    • Lee, Chih‐Yuan;
    • Chang, Chun‐Chao;
    • Wu, Jo‐Hsuan;
    • Liu, Chun‐Jen;
    • Su, Tung‐Hung;
    • Tseng, Tai‐Chung;
    • Chen, Pei‐Jer;
    • Kao, Jia‐Horng
    Publication type:
    Article
    26

    Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2018, v. 48, n. 11/12, p. 1290, doi. 10.1111/apt.15011
    By:
    • Liu, Chen‐Hua;
    • Yu, Ming‐Lung;
    • Peng, Cheng‐Yuan;
    • Hsieh, Tsai‐Yuan;
    • Huang, Yi‐Hsiang;
    • Su, Wei‐Wen;
    • Cheng, Pin‐Nan;
    • Lin, Chih‐Lin;
    • Lo, Ching‐Chu;
    • Chen, Chi‐Yi;
    • Chen, Jyh‐Jou;
    • Ma, Qian;
    • Brooks‐Rooney, Craig;
    • Kao, Jia‐Horng
    Publication type:
    Article
    28
    29

    Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.

    Published in:
    Clinical Infectious Diseases, 2022, v. 75, n. 3, p. 453, doi. 10.1093/cid/ciab971
    By:
    • Liu, Chun Jen;
    • Sheen, I Shyan;
    • Chen, Chi Yi;
    • Chuang, Wan Long;
    • Wang, Horng Yuan;
    • Tseng, Kuo Chih;
    • Chang, Ting Tsung;
    • Yang, Jenny;
    • Massetto, Benedetta;
    • Suri, Vithika;
    • Camus, Gregory;
    • Jiang, Deyuan;
    • Zhang, Fangqiu;
    • Gaggar, Anuj;
    • Hu, Tsung Hui;
    • Hsu, Yu Chun;
    • Lo, Gin Ho;
    • Chu, Chi Jen;
    • Chen, Jyh Jou;
    • Peng, Cheng Yuan
    Publication type:
    Article
    30
    31

    SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.

    Published in:
    2021
    By:
    • Tsung-Yu Tsai;
    • Ming-Ting Huang;
    • Pei-Shan Sung;
    • Cheng-Yuan Peng;
    • Mi-Hua Tao;
    • Hwai-I Yang;
    • Wei-Chiao Chang;
    • An-Suei Yang;
    • Chung-Ming Yu;
    • Ya-Ping Lin;
    • Ching-Yu Bau;
    • Chih-Jen Huang;
    • Mei-Hung Pan;
    • Chung-Yi Wu;
    • Chwan-Deng Hsiao;
    • Yi-Hung Yeh;
    • Duan, Shiteng;
    • Paulson, James C.;
    • Shie-Liang Hsieh;
    • Tsai, Tsung-Yu
    Publication type:
    journal article
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Long‐term risk of end‐stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan.

    Published in:
    Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 8, p. 2247, doi. 10.1111/jgh.15469
    By:
    • Hsieh, Meng‐Hsuan;
    • Bair, Ming‐Jong;
    • Tsai, Pei‐Chien;
    • Tseng, Kuo‐Chih;
    • Lo, Ching‐Chu;
    • Chen, Chi‐Yi;
    • Kuo, Hsing‐Tao;
    • Hung, Chao‐Hung;
    • Lai, Hsueh‐Chou;
    • Peng, Cheng‐Yuan;
    • Wang, Jing‐Houng;
    • Chen, Jyh‐Jou;
    • Lee, Pei‐Lun;
    • Chien, Rong‐Nan;
    • Yang, Chi‐Chieh;
    • Lo, Gin‐Ho;
    • Kao, Jia‐Horng;
    • Liu, Chun‐Jen;
    • Liu, Chen‐Hua;
    • Yan, Sheng‐Lei
    Publication type:
    Article
    41

    Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non‐cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.

    Published in:
    Journal of Gastroenterology & Hepatology, 2019, v. 34, n. 11, p. 1977, doi. 10.1111/jgh.14672
    By:
    • Liu, Chen‐Hua;
    • Shih, Yu‐Lueng;
    • Yang, Sheng‐Shun;
    • Lin, Chih‐Lin;
    • Fang, Yu‐Jen;
    • Cheng, Pin‐Nan;
    • Chen, Chi‐Yi;
    • Peng, Cheng‐Yuan;
    • Hsieh, Tsai‐Yuan;
    • Chiu, Yen‐Cheng;
    • Su, Tung‐Hung;
    • Liu, Chun‐Jen;
    • Yang, Hung‐Chih;
    • Chen, Pei‐Jer;
    • Chen, Ding‐Shinn;
    • Kao, Jia‐Horng
    Publication type:
    Article
    42
    43
    44

    Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.

    Published in:
    Journal of Gastroenterology & Hepatology, 2017, v. 32, n. 12, p. 1998, doi. 10.1111/jgh.13796
    By:
    • Kao, Jia‐Horng;
    • Yu, Ming‐Lung;
    • Peng, Cheng‐Yuan;
    • Heo, Jeong;
    • Chu, Chi‐Jen;
    • Chang, Ting‐Tsung;
    • Lee, Youn‐Jae;
    • Hu, Tsung‐Hui;
    • Yoon, Ki Tae;
    • Paik, Seung Woon;
    • Lim, Young Suk;
    • Ahn, Sang Hoon;
    • Isakov, Vasily;
    • McPhee, Fiona;
    • Hu, Wenhua;
    • Scott Swenson, Eugene;
    • Yin, Philip D;
    • Treitel, Michelle
    Publication type:
    Article
    45

    Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.

    Published in:
    Journal of Gastroenterology & Hepatology, 2016, v. 31, n. 7, p. 1323, doi. 10.1111/jgh.13305
    By:
    • Chuang, Wan‐Long;
    • Chien, Rong‐Nan;
    • Peng, Cheng‐Yuan;
    • Chang, Ting‐Tsung;
    • Lo, Gin‐Ho;
    • Sheen, I‐Shyan;
    • Wang, Horng‐Yuan;
    • Chen, Jyh‐Jou;
    • Yang, Jenny C.;
    • Knox, Steven J.;
    • Gao, Bing;
    • Garrison, Kimberly L.;
    • Mo, Hongmei;
    • Pang, Phillip S.;
    • Hsu, Yu‐Chun;
    • Hu, Tsung‐Hui;
    • Chu, Chi‐Jen;
    • Kao, Jia‐Horng
    Publication type:
    Article
    46
    47
    48
    49
    50